Etanidazole
| Names | |
|---|---|
| Preferred IUPAC name
N-(2-Hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.164.363 |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C7H10N4O4 | |
| Molar mass | 214.181 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Etanidazole is a nitroimidazole drug that was investigated in clinical trials for its radiosensitizing properties in cancer treatment. Administration of etanidazole results in a decrease of glutathione concentration and inhibits glutathione S-transferase. The result is that tissues become more sensitive to the ionizing radiation.